CPAP

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, March 28, 2024
CARE, Sleep apnea, CPAP, Continuous positive airway pressure, Exercise, Environment, VIP, Obstructive sleep apnea, PAP, Shareholder, Webcast, Patient, DME, Sleep, DNA, ODO, AHI, Messenger, Myotherapy, Security (finance), Danaher Corporation, Clinical trial, Therapy, Annual report, Optimism, Dentist, FDA, Food, Pharmaceutical industry

LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Importantly, Vivos believes that governmental investigations of unrelated third parties with non-FDA approved products in the sleep apnea treatment space adversely impacted new Vivos case starts and VIP enrollments during 2023.
  • Vivos’ CARE appliances include the flagship DNA oral appliance, the mRNA oral appliance and the mmRNA oral appliance.
  • Since then, we’ve received high levels of inquiries related to our Vivos CARE products that treat OSA in adults.
  • A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations .

Discreetly Monitor Your Loved Ones from Anywhere, Any Time with Smart Alert Tech - A New, Subscription Free Smart Monitoring System Helping Seniors Stay Home Longer and Age in Place, with Dignity.

Retrieved on: 
Thursday, March 28, 2024
Electricity, Passive, Friends, CPAP, Amazon, Coffee, Google Play, Passive infrared sensor, Motion, Life, App Store (iOS/iPadOS), Love, Television, Mobile phone

LEWISBERRY, Pa., March 28, 2024 /PRNewswire/ -- Smart Alert Tech is designed to keep check of your loved ones, so you don't have to worry. Our product is a simple and unobtrusive way to monitor the people you love and their daily life - only be alerted to interruptions in their routine. Simply determine your loved one's schedule and select a place to mount the sensor or connect the plug with a device you know is used with regularity. Download our App, pair the plug or sensor, and set an alarm. Only receive a push notification if there's a change in their daily pattern. With our system there are no more costly monthly monitoring services. For a onetime fee, families can take comfort and have peace of mind from anywhere, any time.

Key Points: 
  • LEWISBERRY, Pa., March 28, 2024 /PRNewswire/ -- Smart Alert Tech is designed to keep check of your loved ones, so you don't have to worry.
  • Our Wi-Fi enabled, Smart PIR Sensor (Passive InfraRed Sensor) can be placed virtually anywhere with either battery power or plugged in to the wall.
  • Find out more at www.smartalerttech.com
    For more information, visit the App Store , Google Play Store or the Smart Alert Tech website.
  • We are also thrilled to pilot our services with the Lehigh County Office of Aging & Adult Services in Lehigh County, Pennsylvania.

Legal-Bay Lawsuit Funding Provides Update to Recent Weedkiller Lawsuit Settlement News

Retrieved on: 
Monday, March 25, 2024
Hip, SAN, CPAP, Non-Hodgkin lymphoma, Slip, HERE, Cancer, Personal injury, Tobacco

SAN FRANCISCO, March 25, 2024 /PRNewswire/ -- Legal-Bay Presettlement Lawsuit Funding reports that settlements are yet again delayed in the numerous weed killer lawsuits that have dragged on for years. To round up, nearly 30,000 plaintiffs have outstanding suits against a well-known chemicals manufacturer, claiming their product is directly responsible for making them sick. Certain cancers are alleged to have been caused by the glyphosate-based herbicide including non-Hodgkin lymphoma.

Key Points: 
  • Leading pre-settlement funding firm says negligent company continues to use delay tactics to stall payments and final settlement amounts on open cases.
  • SAN FRANCISCO, March 25, 2024 /PRNewswire/ -- Legal-Bay Presettlement Lawsuit Funding reports that settlements are yet again delayed in the numerous weed killer lawsuits that have dragged on for years.
  • Their loan for settlement funding programs are designed to provide immediate cash in advance of a plaintiff's anticipated monetary award.
  • Therefore, terms like settlement loan, loans for lawsuit, loans on settlement, or lawsuit loan funds don't necessarily apply, as the "loan on lawsuit" isn't really a loan at all, but rather a stress-free cash advance.

Sleep Apnea Devices Market, Industry Trends and Global Forecasts, 2035

Retrieved on: 
Friday, March 15, 2024
Diagnosis, ResMed, Non-invasive ventilation, Sleep apnea, CPAP, Growth, Prevalence, APAP, LivaNova, Obstructive sleep apnea, Polysomnography, Ageing, Ventilation, Research, Overalls, Central sleep apnea, Woman, Hub, Interest, USD, Administration, Pharmaceutical industry

The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.

Key Points: 
  • The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.
  • The global sleep apnea diagnostic devices market is categorized into polysomnography devices and home sleep apnea testing devices.
  • The market report features an extensive study of the current market landscape, sleep apnea devices market share, market size, market analysis, market forecast and future opportunities for the sleep apnea companies involved in the development of sleep apnea medical devices and sleep apnea drugs.
  • Sleep Apnea Devices Market Analysis: Sleep Apnea Therapeutic Devices Hold Majority Market Share
    The global sleep apnea devices market is estimated to be worth USD 13.5 billion in 2024.

Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask

Retrieved on: 
Wednesday, March 6, 2024
RMD, SAN, CPAP, Sleep apnea, Sleep, ResMed, ASX, F40, Patient, Claustrophobia, Trial of the century, Mask, COPD, Cosmetics

Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night.

Key Points: 
  • Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night.
  • The AirFit F40 addresses this problem by providing the necessary pressure support in a more comfortable, lower-profile full-face mask.
  • The mask is ideal for people who sleep on their side, are claustrophobic, and want the stability and seal of a universal fit mask in a minimalist design.
  • AirFit F40 masks are available in the U.S., with plans to launch in Canada, followed by EMEA, Latin America, and APAC.

REMSleep Holdings Shareholder Update

Retrieved on: 
Monday, March 4, 2024
ISO, Blood pressure, Incidence, Ageing, Heart, Woman, Inhalation, Atmosphere, International Organization (journal), Dementia, CPAP, OSA, Obstructive sleep apnea, Pressure, Obesity, FDA, OTC, Smoking, Arrhythmia, Sleep, Biocompatibility, Exhalation, CHF, Risk, International Organization for Standardization, Consultant, Type 2 diabetes, Frustration, Engineering, BMI, DSM-IV codes, Non-invasive ventilation, Type, National Council, Respiration, Medical device

CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.

Key Points: 
  • CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.
  • We have had numerous inquiries asking for REMSleep regulatory status update.
  • REMSleep consultants are confident we will receive our 510(K) and we will never give up until we are successful.
  • REMSleep has addressed this problem by developing a novel CPAP nasal pillow interface that has been engineered to reduce pressure and enable better airflow.

Signifier Medical Technologies Announces Publication of a New Study Exploring Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea

Retrieved on: 
Thursday, March 7, 2024
Health, Medical Devices, Health Technology, Other Health, General Health, Research, Science, Diabetes, Freedom, CPAP, Patient satisfaction, Sleep apnea, Quality of life, Quality-adjusted life year, Treatment, Obstructive sleep apnea, Continuous positive airway pressure, Technology assessment, ICER, Prevalence, Hypertension, Life imprisonment, PAP, Patient, Canadian International Council, NMES, Signified and signifier, DRS, Health technology

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."

Key Points: 
  • Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."
  • Shan Liu, Jan Pietzsch, and a collaborative research team explores the cost-effectiveness of using neuromuscular electrical stimulation (NMES) as a treatment option for patients with mild obstructive sleep apnea (OSA).
  • The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no treatment.
  • "We are excited to see the results of this study reinforce the potential of neuromuscular electrical stimulation as a revolutionary treatment option for individuals with mild obstructive sleep apnea," states Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier.

FDA Clears AIOMEGA’s AIO Breathe, for Treatment of Obstructive Sleep Apnea

Retrieved on: 
Wednesday, February 28, 2024
Cardiology, Biotechnology, General Health, Health, FDA, Medical Devices, Fitness & Nutrition, Dental, Heart, Hearing, CPAP, OSA, MD, Obesity, Obstructive sleep apnea, Food, AIO, Sleep, Diabetes, Stroke, MBA, Mouth, Snoring, Patient, Atrial fibrillation, Jaw, Pharmaceutical industry

AIOMEGA , a Texas biomedical company, announced that AIO BREATHE, their medical device that treats Obstructive Sleep Apnea, has been cleared by the Food and Drug Administration.

Key Points: 
  • AIOMEGA , a Texas biomedical company, announced that AIO BREATHE, their medical device that treats Obstructive Sleep Apnea, has been cleared by the Food and Drug Administration.
  • AIO BREATHE is a “new mandibular repositioning device” designed by Tyler, Texas based Board Certified Sleep Physician Dr. Raghavendra V. Ghuge , MD, MBA, DABSM, FAASM.
  • “I designed AIO BREATHE, supported by multiple patents, to overcome several shortcomings of conventional oral appliances used for treatment of OSA,” said Dr. Ghuge
    AIO Breathe acts by increasing the patient’s airway during sleep, improving ability to exchange air, thereby reducing the tendency to snore and alleviating signs of obstructive sleep apnea.
  • AIO Breathe is intended to reduce or alleviate snoring and mild to moderate Obstructive Sleep Apnea (OSA) while sleeping in adults.

Sleep Apnea Symptoms Linked to Memory and Thinking Problems

Retrieved on: 
Monday, March 4, 2024
Social media, Nervous system, Alzheimer's disease, Boston Medical Center, CPAP, Dementia, Education, Sleep apnea, Blood, Quality of life, Thought, Sleep, Continuous positive airway pressure, Stroke, Confusion, Risk, Annual general meeting, DSM-IV codes, Migraine, AAN, Multiple sclerosis, Parkinson's disease, Memory, Concussion, MPH, Headache, Epilepsy, Brain, Research, American Academy, Pharmaceutical industry

"Our study found participants who had sleep apnea symptoms had greater odds of having memory or thinking problems."

Key Points: 
  • "Our study found participants who had sleep apnea symptoms had greater odds of having memory or thinking problems."
  • Of those with symptoms, 357 people, or 33%, reported memory or thinking problems compared to 628 people, or 20% of people without sleep apnea symptoms.
  • After adjusting for other factors that could affect memory and thinking problems, such as age, race, gender and education, researchers found that people who reported sleep apnea symptoms were about 50% more likely to also report having memory or thinking problems compared to people who did not have sleep apnea symptoms.
  • Additional studies are needed following people's sleep apnea, memory and thinking symptoms over time.

Sleep Center of Littleton Introduces an Alternative to CPAP Therapy

Retrieved on: 
Wednesday, February 28, 2024
CPAP, Sleep apnea, Sleep, Patient, Hope, Tongue, Mask, Travel, Jaw, Pharmaceutical industry

LITTLETON, Colo., Feb. 28, 2024 /PRNewswire/ -- Sleep Center of Littleton, a leading provider of sleep apnea treatment, is excited to announce the introduction of an innovative alternative to Continuous Positive Airway Pressure (CPAP) therapy.

Key Points: 
  • LITTLETON, Colo., Feb. 28, 2024 /PRNewswire/ -- Sleep Center of Littleton, a leading provider of sleep apnea treatment, is excited to announce the introduction of an innovative alternative to Continuous Positive Airway Pressure (CPAP) therapy.
  • Recognizing these challenges, Sleep Center of Littleton is now offering an excellent alternative: oral appliance therapy.
  • "The introduction of oral appliance therapy is a game-changer for individuals who have struggled with CPAP therapy," said Dr. Thomas R. Froning, a Qualified Sleep Dentist and founder of Sleep Center of Littleton.
  • For individuals who have struggled with CPAP therapy or are searching for an effective alternative, Sleep Center of Littleton offers a ray of hope.